COVID-19 Funding Opportunities

COVID-19 Research Grants for Combating the coronavirus crisis

Various government agencies, companies, and foundations have announced non-dilutive funding opportunities to encourage research and development to address the novel Coronavirus pandemic. Some of these opportunities allow applicants to propose new projects addressing COVID-19, while others provide funding to expand the scope of existing awards to include COVID-19-related research.

As the COVID-19 situation continues to develop, EGC will maintain an updated list of relevant funding opportunities here. Click below to be notified as new COVID-19 research grants are announced.

Expand/Collapse All
Biomedical Advanced Research and Development Authority (BARDA)

BARDA has updated its Broad Agency Announcements (BAAs) to focus exclusively on addressing the COVID-19 threat.  BARDA’s annual budget of $512 Million has been supplemented by an additional $3.5 billion through the recently passed Coronavirus Aid, Relief, and Economic Security (CARES) Act.  The additional funding is allocated for necessary expenses of manufacturing, production, and purchase of various supplies and services.


View Solicitation

Topic: Products to diagnose, prevent or treat novel coronavirus infections
Due Date: Rolling, through 10/31/2020
Budget: Unlimited

Division of Research, Innovation & Ventures (DRIVe) BAA

View Solicitation

Topics: Diagnostic assays, screening and model development, vaccines, advanced manufacturing.

Due Date: Abstract submissions due by 5PM ET on 6/30/2020.
Budget: $750,000


While CoronaWatch is not a direct funding mechanism, the U.S. government seeks information from stakeholders on available medical countermeasures in development for COVID-19. A CoronaWatch meeting is held by interactive webinar, in which the presenting team displays slides and engages with government personnel.  A CoronaWatch meeting is encouraged prior to applying for BARDA funding, so that organizations can better align their product development with government priorities.

Request CoronaWatch Meeting

National Institutes of Health (NIH) NEW! DEADLINE APPROACHING
NIH Director’s Emergency Transformative Research Awards (R01 Clinical Trial Optional)

View Solicitation

Description: The NIH Director’s Transformative Research Award Program supports individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies with the potential to produce a major impact on SARS-CoV-2 prevention, preparation, or response. No preliminary data are required.

Topics: Any area of research relevant to the prevention of, preparation for, or response to coronavirus SARS-CoV-2, including behavioral/social science research, research on health disparities, novel therapeutics, and other related topics

Due Dates: 9/30/2020 (opens 8/30/2020)
Budget: Not limited, but must be commensurate with the scope of the proposed research

Notices of Special Interest (NOSI)

Multiple NIH Institutes have issued a Notice of Special Interest (NOSI) to provide funding for research topics related to COVID-19.  For most of these opportunities, the applicant must have an active award through the Institute with sufficient time remaining to complete all studies proposed.

National Institute on Aging (NIA), National Institute of Mental Health (NIMH)
NOSI: Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)
  • PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements for NIH grantees applying to expand the scope of their active grant.
  • PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements to provide funds for NIH grantees where the work proposed in the supplement is fully within the scope of the ongoing grant.

Topics:  NIA – Mission critical areas as they relate to the COVID-19 pandemic. NIMH – Applications addressing care for new or worsening mental health needs and/or suicide risk in midlife and older age adults will be seen as a high priority.

Due Date: Rolling until 5/1/2021
Budget: Limited to no more than that amount of the current parent award.

National Heart, Lung, Blood Institute (NHLBI)
NOSI: Availability of Emergency Competitive Revisions on Coronavirus Disease 2019 (COVID-19) for Currently Active NHLBI Phase I-III Clinical Trials

Description: NHLBI is issuing this Notice of Special Interest due to the urgent need for early phase clinical trials to evaluate new or existing interventions that may prevent or treat COVID-19. NHLBI seeks to leverage existing clinical trials expertise and, using NHLBI programs that are actively conducting Phase I-III clinical trials, to rapidly initiate and conduct Phase I-Phase I/II (bridging) clinical trials in patients at risk for SARS-CoV-2 infection and/or patients with COVID-19.

Topics: Safety and efficacy of interventions for primary prevention and/or treatment of COVID-19, associated clinical phenotypes, and surrogate outcomes, relevant to heart, lung, and blood (HLB) diseases

Due Dates: 10/5/2020
Budget: Not specified

NOSI: Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)

Topic: COVID-19 related research including host response, associations with heart, lung, and blood (HLB) diseases, potential impacts on transfusion safety, and clinical outcomes of infected individuals.

Due Date: Rolling, through 10/5/2020
Budget: Not specified

National Institute of Allergy and Infectious Diseases (NIAID)
NOSI: Select Research Areas for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

Description: NIAID is issuing this Notice of Special Interest to highlight the need for research on SARS-CoV-2 and COVID-19 in select scientific areas using the R03, R41/42, and R43/44 funding mechanisms.


  • Studies to understand critical aspects of viral infection, replication, pathogenesis, and transmission
  • Studies on the evolution and emergence of SARS-CoV-2 viruses including the identification of factors that affect viral host-range and virulence
  • Development of sensitive, specific, and rapid clinical diagnostic tests for SARS-CoV-2
  • Development of SARS-COV-2 therapeutic candidates, especially broad-spectrum therapeutics against multiple coronavirus strains
  • Identification and evaluation of the innate, cellular and humoral immune responses to SARS-CoV-2 infection, including, but not limited to: cross-reactive antibodies from individuals exposed to SARS-CoV-2 and other coronaviruses; viral epitopes critical for T cell activation or antibody binding and neutralization; immune-mediated pathology or host factors that might predispose to severe infection; and studies to examine duration of protection or the potential for reinfection
  • Development of SARS-CoV-2 vaccine candidates, including approaches for pan-coronavirus protection, that include emerging antigen design strategies, novel platforms or delivery approaches, adjuvants, or assessing cross-neutralization potential of SARS-CoV vaccine candidates

Due Dates: Due dates on or after 6/16/2020
Budget: See the corresponding funding opportunity announcements for details

Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

R21 (Clinical Trial Not Allowed)
R01 (Clinical Trial Not Allowed)

Description: NIAID has announced an expedited funding mechanism for research on SARS-CoV-2 and/or COVID-19.


  • Studies to understand critical aspects of viral transmission, infection, replication and pathogenesis
  • Identification and characterization of the onset and duration of immunity in healthy and at-risk populations
  • Virologic and serologic surveillance studies and natural history studies to understand the origin of the virus including the animal host reservoir, potential intermediate hosts, factors leading to spill over events, evidence of continued spill over events and studies at the human-animal interface
  • Studies to assess and characterize the natural history and long-term consequences of SARS-CoV-2 infection in various human populations including at risk populations
  • Development or improvement of clinical diagnostic tests for SARS-CoV-2 to increase the sensitivity, specificity and ability to provide rapid results
  • Development and testing of SARS-CoV-2 therapeutic candidates in relevant in vitroex vivo or animal models
  • Development of SARS-CoV-2-specific or broadly protective coronavirus vaccine candidates
  • Studies to inform the development of vaccination strategies for at-risk populations including use of age-specific adjuvants or novel antigen formulations/dosing
  • Development of assays and animal models to evaluate the potential of enhanced disease after vaccination for SARS-CoV-2
  • Assess animal models for SARS-CoV-2 and how the models compare to human infection including animal models that represent at risk populations (elderly, immunocompromised, very young, pregnant models)
  • Development of animal models for transmission experiments;
  • Development of organoid culture models and/or ex vivo explant models
  • Computational modeling studies to identify and evaluate interventions to protect at-risk populations and for making public health policy decisions for control and mitigation measures
  • Study interactions and impact between SARS-CoV-2 and other respiratory pathogens including influenza (e.g., co-infections, interference)
  • Comparative studies of SARS-CoV-2 to other coronaviruses including SARS-CoV-1 and MERS
  • Data science approaches to develop algorithms, models, and informatics solutions

Due Dates: Accepting applications on a rolling basis until 4/30/2021
Budget: $275,000 in direct costs for R21; No specified limit for R01

Partnerships for Countermeasures against Select Pathogens (R01 Clinical Trials Not Allowed)

Description: The purpose of this Funding Opportunity Announcement (FOA) is to solicit research applications for milestone-driven projects focused on preclinical development of lead candidate therapeutics, vaccines and related countermeasures against select NIAID Emerging Infectious Diseases/Pathogens. Applications must include a Product Development Strategy attachment and demonstrate substantive investment by at least one industrial participant.

Topics: Preclinical development of lead candidate therapeutics, vaccines and related countermeasures against select NIAID Emerging Infectious Diseases/Pathogens, including SARS-CoV-2.

Due Dates: 6/29/2020
Budget: $750,000 in direct costs and $300,000 in equipment costs in Year 1; $750,000 in direct costs per year thereafter

NOSI: Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

Topics: Viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19.

Due Date: Rolling until 3/25/2021
Budget: Not Specified

National Institute of General Medical Sciences (NIGMS)
NOSI: Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2

Topics: Predictive models for the spread of SARS-CoV-2 and other related infectious agents (all relevant grants). Repurposing or modification of diagnostic tools currently under development to enable rapid detection of SARS-CoV-2 infection; rapid development of potential therapeutic agents for COVID-19 (SBIR/STTR grants only).

Due Date: Rolling, through 2/6/2021
Budget: Not Specified

National Center for Advancing Translational Sciences (NCATS) DEADLINE APPROACHING
NOSI: Availability of Emergency Competitive Revisions and Administrative Supplements to Clinical and Translational Science Award (CTSA) Program Awards to Address 2019 Novel Coronavirus Disease (COVID-19) Public Health Needs

The NCATS is seeking proposals for emergency administrative supplements and competitive revisions to existing UL1 and U24 CTSA Program awards to address COVID-19 public health needs


  • Digital health platforms
  • Planning of COVID-19 trials
  • eConsent support
  • Platforms for meta-analysis of COVID-19 trials
  • Clinical data provision
  • Clinical studies and trials of COVID-19 interventions
  • Assessment of infectious or convalescent status

Due Dates: Applications will be reviewed on a rolling basis through 11/10/2020
Budget: Not specified, but may exceed the current amount of the parent award

NOSI: Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Heath Need

Topics: Use of informatics solutions to diagnose cases and the use of CTSA-supported core resources to facilitate research on COVID-19 and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

PA-18-591 – Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

Due Dates: 11/2/2020
Budget: Application budgets are limited to no more than the amount of the current parent award and must reflect the actual needs of the proposed project.

PAR-19-099 – Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative Innovation Award (U01 Clinical Trial Optional)

Due Dates: 7/10/2020, 11/9/2020, 3/8/2021, 7/9/2021
Budget: $400,000 – $750,000

PAR-19-100 – Limited Competition: Clinical and Translational Science Award (CTSA) Program: Exploratory Collaborative Innovation Awards (R21 Clinical Trial Optional)

Due Dates: 7/10/2020, 11/9/2020, 3/8/2021, 7/9/2021
Budget: $275,000 (direct costs)

PAR-19-337 – Limited Competition: Competitive Revision Awards for the Clinical and Translational Science Award (CTSA) Program (U54 Clinical Trial Optional).

Due date: 9/25/2020
Budget: $750,000/year in direct costs excluding consortium/contractual F&A costs.

NOSI: Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19)

Topics: Using innovative processes to identify the therapeutic/indication pair for use to treat COVID-19.

PAR-17-465 – Bench Testing Therapeutic/Indication Pairing Strategies (UG3/UH3)

Due Dates: 6/26/2020
Budget: $200,000 direct costs/year for UG3 proposals and $100,000 direct costs for UH3 proposals.

PA-18-462 – Clinical Trial Planning: Therapeutic/Indication Pairing Strategies (U34) (Clinical Trial Not Allowed)

Due Dates: 6/16/2020, 10/16/2020
Budget: $225,000 (direct costs)

PAR-18-332 – Clinic Testing Therapeutic/Indications Pairing Strategies (U01 Clinical Trial Required)

Due Dates: 6/5/2020, 10/5/2020
Budget: $3,000,000 in direct costs per year.

NOSI: Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus

Topic: Use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

Due Date: Rolling through 01/26/2022
Budget: 25% total costs of current parent award

National Institute of Drug Abuse (NIDA)
NOSI: Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus

Topic: NIDA is interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders.

Due Date: Rolling, through 3/31/2021
Budget: Maximum of $100,000 direct costs per year for 2 years.  Higher budgets may be considered with justification.

National Institute on Deafness and Other Communication Disorders (NIDCD) NEW!
NOSI: NIDCD is Interested in Supporting Research on the Impact of COVID-19 on Mission Specific Sensory and Communication Disorders

Description: NIDCD invites applications for research on COVID-19 in relation to NIDCD’s scientific programs of hearing, balance, taste, smell, voice, speech, and language.

Topics: Topics include, but are not limited to, the following:

  • The effects of prolonged oral intubation on laryngeal function and voice production
  • Short-term and long-term effects of COVID-19 on the auditory, vestibular, or olfactory systems
  • The prevalence, onset, and resolution of acquired deficits (i.e., HBTSVSL) among patients with COVID-19 across the lifespan and in association with various underlying genetic predispositions and health conditions
  • The molecular mechanisms underlying chemosensory dysfunction due to SARS-CoV-2 infection
  • The impact of stress/isolation on speech, language or fluency recovery/development in children or adults
  • The impact of potential congenital transmission of maternal SARS-CoV-2 infection to the newborn in relation to the auditory, vestibular, olfactory, or vocal function and/or the impact on speech production or language acquisition
  • Potential ototoxicity from therapeutics or vaccination related to COVID-19
  • Worsening of communicative function because of physical distancing, sheltering in place, and wearing of protective personal equipment during mitigation of this infectious pandemic
  • Telehealth service delivery to individuals with communication disorders
  • Multidisciplinary collaborative teams including clinicians, basic biologists, geneticists, quantitative scientist, epidemiologists, or other researchers to study COVID-19 related human conditions and behaviors, bioethical considerations, health-service delivery, health services in low-resource areas, and health disparities within NIDCD mission areas

Due Dates: Various program-specific due dates on or after 10/5/2020
Budget: Varies by program

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NOSI: Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIDDK

Topics: Direct action of the virus on kidney, gastrointestinal tract function, and the endocrine/metabolic system, and the collection of biosamples that will inform the understanding of renal, gastrointestinal, and endocrine/metabolic sequelae of viral infection.

Due Date: Rolling through 6/2/2020
Budget: Lesser of current year direct cost budget or $500,000

National Institute of Biomedical Imaging and Bioengineering (NIBIB)

NIBIB has issued a shared set of topics and three separate NOSIs for current grantees, SBIR/STTR applicants, and all other applicants:

Current Grantees NOSI
All Other Applicants NOSI

Topics: Rapid diagnostics, wearable/implantable sensors, digital health platforms, healthcare training platforms, robotic technologies to limit caregiver exposure, ventilators, and disinfectant technologies

Due Date: Varies by NOSI
Budget: Varies by NOSI

Rapid Acceleration of Diagnostics (RADx)

Description: NIBIB is providing substantial support to accelerate the development, validation, and commercialization of innovative point-of-care and home-based tests, as well as improvements to  clinical laboratory tests, that can directly detect SARS-CoV-2, the virus that causes COVID-19. NIBIB will support the full range of product development including, commercialization and product distribution. RADx will support novel solutions that build the U.S. capacity for SARS-CoV-2 testing up to 100-fold above what is achievable with standard approaches.

Topics: SARS-CoV-2 diagnostic testing technologies in two stages:

  • Early stage: transformative innovations based on novel testing strategies that have potential for major scale up
  • Advanced stage: modification and optimization of existing SARS-CoV-2 testing approaches, including clinical laboratory tests, that can dramatically increase testing capacity

Due Dates: Rolling
Budget: Not specified

National Institute of Neurological Disorders and Stroke (NINDS)
NOSI: Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System

Description: NINDS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and on biological effects on the nervous system of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Research of interest must fall within NINDS’s scientific mission, which is to support basic, translational, and clinical neuroscience research to expand fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

Topics: Biology, pathophysiology, prevention, diagnosis, sequelae, or treatment of the 2019 Novel Coronovirus

Due Dates: Applications accepted on a rolling basis until 4/14/2021
Budget: $200,000 in direct costs

Office of Strategic Coordination (OSC) DEADLINE APPROACHING
NOSI: Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

Description: The Office of Strategic Coordination (OSC), which manages the Common Fund, is issuing this Notice of Special Interest to stimulate innovative research on SARS-CoV-2 and COVID-19. OSC seeks new, innovative perspectives and approaches to the prevention of, preparation for, or response to coronavirus SARS-CoV-2, domestically or internationally.

Topics: Any relevant area of innovative research is welcome, including behavioral/social science research, research on health disparities, novel therapeutics, and other related topics.

Due Dates: Accepting applications on a rolling basis until 6/19/2020
Budget: Should not exceed the annual amount of the current parent award

National Library of Medicine (NLM) DEADLINE APPROACHING
NOSI: Data Driven Research on Coronavirus Disease 2019 (COVID-19) (R21)

Description: NLM is issuing this Notice of Special Interest to highlight the urgent need for innovative high-risk/high-impact research on SARS-CoV-2 and COVID-19 in relation to NLM’s strategic goal of fostering data driven research.

Topics: NLM is encouraging the submission of R21 applications to address the following research areas of interest:

  • Methods for mining clinical data that can be used to identify or predict presence of COVID-19 in biomedical phenotype data, or other relevant topics, such as discovery of risks for infection by SARS-Cov-2 viruses and the use of standard terminologies for these viruses in federated health data sets
  • Public health surveillance methods that mine genomic, viromic, health data, environmental data and/or data from other pertinent sources such as social media, to identify the spread and impact of SARS-Cov-2

Due Dates: 6/16/2020
Budget: $275,000 in total direct costs

National Institute of Dental and Craniofacial Research (NIDCR)
NOSI: Availability of Urgent Competitive Revisions and Administrative Supplements for Coronavirus Disease 2019 (COVID-19) Research within the Mission of NIDCR

Description: The National Institute of Dental and Craniofacial Research (NIDCR) has issued a Notice of Special Interest to highlight the urgent need for research on COVID-19 and will place a high priority on topics that would be of immediate and high impact to protect and ensure the safety of personnel and patients in dental practices.


  • Prevention of SARS-COV-2 transmission
  • Improvements in the detection and diagnosis of COVID-19
  • Acquisition of a more robust understanding of SARS-CoV-2 pathogenesis
  • Influence and interaction of sex (a biological variable) and gender (a social construct), race and ethnicity in relation to COVID-19
  • COVID-19 risk, prevention, and health outcomes

Due Dates: 11/2/2020
Budget: $150,000 in total direct costs

National Center for Complementary and Integrative Health (NCCIH)
NOSI: Availability of Administrative Supplements & Urgent Competitive Revisions to NCCIH Grants for Natural Product Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) & Coronavirus Disease 2019 (COVID-19)

Description: The National Center for Complementary and Integrative Health (NCCIH) has announced the availability of funds for Administrative Supplements or Urgent Competitive Revisions to promote research on the effects of natural products alone or in combination with other complementary and integrative health approaches on SARS-CoV-2 and COVID-19.

Topics: Research on the therapeutic and/or mechanistic effects on SARS-CoV-2/COVID-19 of natural product–based complementary remedies including, but not limited to: herbal therapies, vitamins, supplements, probiotics, microbial therapies, and Chinese medicine herbal preparations.

Due Dates: Applications are accepted on a rolling basis through 8/17/2020.
Budget: $150,000 in direct costs

NIH Office of the Director
NOSI: Administrative Supplements to Existing NIH ECHO Cooperative Agreements (Admin Supp – Clinical Trial Not Allowed) for Coronavirus Disease 2019 (COVID-19) – related Research

Description: The Office of The Director of the NIH has issued a notice of special interest to encourage eligible Environmental influences on Child Health Outcomes (ECHO) cohort grantees to apply for an administrative supplement aimed at fostering time-sensitive science related to the COVID-19 pandemic.


  • Impact on ECHO health outcomes of having probable or definite COVID-19 infection, including interactions with other early exposures of interest in ECHO. ECHO Program Office encourages addressing pre-/peri-/postnatal outcomes.
  • Impact on psychosocial, behavioral, economic, health services, or health outcomes of living during the time of the COVID-19.
  • Impact on best practices for implementing the ECHO-wide Cohort data collection protocol during or after the COVID-19 pandemic. Examples of research topics include but are not limited to:
    • Impact on research staff, participants, operations, data completeness, or data quality of pausing cohort operations, and ways to mitigate those impacts.
    • Introducing new approaches to informed consent, data or specimen collection, return of results, or other research-related activities.

Due Dates: 6/22/2020
Budget: $200,000

National Cancer Institute NEW!
Emergency Awards: Research Projects in SARS-CoV-2 Serological Sciences (U01 Clinical Trial Optional)

Description: The NCI has announced the availability of grant funding through the cooperative agreement mechanism U01 for SARS-CoV-2 research projects that will be part of a Serological Sciences Network (SeroNet).


  • Identifying and advancing research opportunities to characterize the immune responses elicited by SARS-CoV-2 viral infection
  • Understanding the mechanisms driving the serological, humoral, and cellular immune responses
  • Determining host, genetic, and environmental modifiers of the immune response
  • Determining the serological correlates of disease pathogenesis and protection against future infection
  • Defining access, communication, and implementation barriers related to SARS-CoV-2 serological testing

Due Dates: 7/22/2020
Budget: $500,000 in direct costs

National Science Foundation (NSF)
Dear Colleague Letter on the Coronavirus

View Letter

The NSF encourages investigators to use existing NSF funding mechanisms to submit proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge.

For proposals of up to $200K, NSF encourages using the Rapid Response Research (RAPID) funding mechanism, which allows NSF to receive and review proposals having a severe urgency.

Dear Colleague Letter: Provisioning Advanced Cyberinfrastructure to Further Research on the Coronavirus Disease 2019 (COVID-19)

View Letter

The Office of Advanced Cyberinfrastructure (OAC) within the Directorate for Computer and Information Science and Engineering is inviting RAPID proposals and supplemental funding requests to existing awards that address COVID-19 challenges through data and/or software infrastructure development activities.

Department of Defense (DOD) DEADLINE APPROACHING
Defense Logistics Agency

DoD SBIR 20.2 – Phase I, Phase II, and Direct-to-Phase II

Phase I & Phase II Announcement
Direct-to-Phase II Announcement
Broad Agency Announcement

Description: The Defense Logistics Agency (DLA) has topics for Phase I, Phase II, and Direct-to-Phase II submissions to the DoD SBIR 20.2 Broad Agency Announcement that request novel approaches for the detection of and protection from emerging viral pandemics.


  • DLA202-D011 Novel Approaches for Detection of and Protection from Emerging Viral Pandemics (Ph I, II)
  • DLA202-D013 Novel Approaches for Detection of and Protection from Emerging Viral Pandemics (Direct to Ph II)

Due Dates: 7/2/2020
Budget: $100,000 for Phase I (up to $252,000 with Program Manager approval); $1,000,000  for Phase II (up to $1,600,000 with Program Manager approval)

Congressionally Directed Medical Research Programs (CDMRP) DEADLINE APPROACHING

Peer Reviewed Medical Research Program (PRMRP)

Three of the FY20 PRMRP mechanisms are focused on Emerging Viral Diseases and Respiratory Health.

PRMRP Home Page


Due Date: Letter of Intent – Starting 5/28/2020, Full Application – Starting 6/12/2020
Budget: Varies by Program

US Department of Agriculture (USDA)
National Institute of Food and Agriculture (NIFA)

In response to the current need for more COVID-19 information, certain NIFA programs will allow submission of COVID-19 relevant projects outside of their normal deadlines.

Agriculture and Food Research Initiative (AFRI)

View Solicitation

Topics: Focus areas of interest include, but are not limited to the following:

  • Animal Nutrition, Growth and Lactation (A1231)
  • Critical Agricultural Research and Extension (CARE) (A1701)
  • Diseases of Agricultural Animals (A1221)
  • Food Safety and Defense (A1332)
  • Foundational Knowledge of Plant Products (A1103)
  • Economics, Markets, and Trade (A1641)

Due Date: Varies by Program
Budget: $1,000,000

Distance Learning and Telemedicine (DLT) Grants

View Solicitation

Topics: Enable and improve distance learning and telemedicine services in rural areas. Support the use of telecommunications-enabled information, audio and video equipment, and related advanced technologies to increase rural access to education, training, and health care resources for students, teachers, medical professionals, and rural residents.

Due Date: 7/13/2020
Budget: $50,000 – $1,000,000

Department of Homeland Security

Innovative Commercial Products in Support of Coronavirus (COVID-19) Response – Commercial Solutions Opening Pilot Program (CSOP)

View Solicitation

Description: The DHS is seeking innovative commercial products for exposure detection, prevention, containment and treatment of COVID-19 and similar microbial threats. Through this contract opportunity, the DHS will rapidly acquire, test, and deploy suitable products.

Topics: Proposed innovative commercial products may be, but are not limited to, products that:

  • Supplement shortages and/or emerging needs for personal protective equipment
  • Enhance or expedite screening capabilities
  • Enhance or expedite facility cleaning capabilities
  • Extend testing capabilities
  • Utilize technology to support the COVID-19 response
  • Convert existing production and logistics operations to support the COVID-19 response.

Due Dates: Proposals are accepted and considered on a rolling basis until 8/31/2020
Budget: Dependent on the contract


DRL FY19 Countering Corruption amid COVID-19

View Solicitation

Description: The U.S. Department of State, Bureau of Democracy, Human Rights and Labor (DRL) announces an open competition for organizations interested in submitting applications in support of the goal of combating corruption arising in response to the COVID-19 pandemic.

Topics: Anti-corruption solutions

Due Dates: 6/12/2020
Budget: $1,000,000

Wellcome, Bill & Melinda Gates Foundation, and Mastercard

The Bill & Melinda Gates Foundation, Wellcome, and Mastercard have committed up to $125 million in seed funding to speed-up the response to the COVID-19 epidemic by identifying, assessing, developing, and scaling-up treatments. The COVID-19 Therapeutics Accelerator will play a catalytic role by accelerating and evaluating new and repurposed drugs and biologics to treat patients with COVID-19 in the immediate term, and other viral pathogens in the longer-term.

View Announcement

Topics: The Accelerator is seeking partners for the following activities:

  • Identifying candidate compounds by testing approved drugs for activity against COVID-19, screening libraries of compounds with confirmed safety data, and considering new investigational compounds and monoclonal antibodies.
  • Developing drugs or monoclonal antibodies that pass initial screening.
  • Scaling up production and commercialization of successful drugs and monoclonal antibodies.

Due Date: Not Specified
Budget: Not Specified; Total Program Budget – $125,000,000

National Institute of Standards and Technology (NIST)

NIST Manufacturing USA National Emergency Assistance Program

NIST invites applications from the 2,000 current Manufacturing USA institutes, including small manufacturers, two-thirds of Fortune 50 U.S. manufacturers, and nearly every top ranked research and engineering university in the United States.

View Solicitation

Topic: Projects should focus on responding to the COVID-19 pandemic. Projects may include medical countermeasures; non-medical countermeasures; leveraging institute capabilities to strengthen state and community resilience; grants to companies and technical support to accelerate productions of critical materials, equipment, and supplies; creation of additional production facilities; technology roadmapping for pandemic response and recovery; reshoring the manufacture of critical conventional drugs and ensuring supply chain for critical materials related to pandemic response; or workforce development and training for a skilled advanced manufacturing workforce.

Due Date: Rolling
Budget: $250,000 – $10 million

Agency for Health Care Research and Quality (AHRQ) DEADLINE APPROACHING

Novel, High-Impact Studies Evaluating Health System and Healthcare Professional Responsiveness to COVID-19 (R01)

Description: The Agency for Health Care Research and Quality invites R01 grant applications for funding to support novel, high-impact studies evaluating the responsiveness of healthcare delivery systems, healthcare professionals, and the overall U.S. healthcare system to the COVID-19 pandemic.


  • Effects on quality, safety, and value of health system response to COVID-19
  • Role of primary care practices and professionals during the COVID-19 epidemic
  • Understanding how the response to COVID-19 affected socially vulnerable populations and people with multiple chronic conditions
  • Digital healthcare, including innovations and challenges encountered in the rapid expansion of telehealth response to COVID-19

Due Dates: 6/15/2020
Budget: $1,000,000 ($500,000 per year for up to 2 years)

Coalition for Epidemic Preparedness Innovation (CEPI)

Achieving an unprecedented acceleration of vaccine development and global manufacturing capacity to prevent COVID-19

Description: CEPI has opened an additional funding opportunity for the rapid development of vaccines against COVID-19, with a goal of achieving licensure/emergency authorization in 12-18 months or less and ensuring the availability of sufficient doses for widespread global deployment as soon as possible in 2021.

Topics: Development of a COVID-19 vaccine for large-scale production

Due Dates: Applications accepted on a rolling basis until at least 6/30/2020
Budget: Not specified

Massachusetts Institute of Technology (MIT) DEADLINE APPROACHING

MIT Solve: Health Security and Pandemics Challenge

Description: MIT Solve is seeking improved solutions for the prevention of, accurate detection of, and rapid response to infectious diseases.

Topics: MIT Solve is seeking tech innovations in two main areas:

1) Slowing and tracking the spread of an emerging outbreak by

  • improving individual hygiene
  • developing low-cost rapid diagnostics
  • analyzing data that inform decision making
  • providing tools that support and protect health workers

2) Preventing and mitigating disease outbreaks through efforts such as

  • strengthening access to affordable primary healthcare systems
  • enhancing disease surveillance systems
  • improving healthcare supply chains

Due Dates: 6/18/2020
Budget: $10,000 for each selected Solver team; eligible Solver teams may also apply for The Elevate Prize for Health Security, awarded by The Elevate Prize Foundation, which provides a minimum of $300,000 in funding over two years for the winning Solver team.

California Institute for Regenerative Medicine

Special Call for COVID-19 Projects – Partnership Opportunities in Support of Discovery, Translational and Clinical Trial Stage Activities

View Solicitation

Description: Focusing on the development of therapies for COVID-19, CIRM has issued a special announcement to support promising discovery, preclinical and clinical trial stage projects that could quickly advance new treatments.


  • Cell-based COVID-19 therapies that use, target, or are manufactured using stem or progenitor cells
  • Gene therapies for COVID-19 that are intended to replace, regenerate, or repair the function of aged, diseased, damaged, or defective cells, tissues, and/or organs

Due Date: Biweekly on an ongoing basis
Budget: $150,000 – $750,000 depending upon product stage

Amazon Web Services (AWS) Diagnostic Development Initiative (DDI)

View Solicitation

Topics: Using AWS to support research-oriented workloads for the development of point-of-care diagnostic (testing that can be done at home or at a clinic with same-day results) and other diagnostic techniques.  Initial emphasis will be on the COVID-19 coronavirus disease, but other infectious disease diagnostic projects will be considered.

Due Date: Submissions accepted until 6/30/2020. Funding decisions will be made within 45 days of submission.
Budget: Awards will consist of promotional credits to be put toward AWS resource usage.

Fast Grants

Fast Grants are available exclusively to PIs at academic institutions already working on COVID-19 related projects that could help with the pandemic within the next six months.

View Solicitation

Topics: All COVID-19 related science

Due Date: Rolling, award decisions made in 48 hours.
Budget: $10,000 – $500,000

Patient-Centered Outcomes Research Institute (PCORI)

PCORI is requesting enhancements to existing Research Projects and Engagement Awards.

COVID-19-Related Enhancements to Existing PCORI-Funded Research Projects

COVID-19-Related Enhancements to Existing PCORI-Funded Engagement Awards

Topics: Modest additions to existing aims as they relate to COVID-19 or new aims designed to produce useful knowledge related to COVID-19 and the original award.  Taking advantage of natural experiments in health system, state, and provider responses is strongly encouraged.

Due Date: Rolling submissions
Budget: $500,000 for Research Projects; $150,000 for Engagement Awards

Call for Code & IBM
2020 Call for Code Global Challenge

Description: The 2020 Call for Code Global Challenge is a competition in which Call for Code is asking innovators to create practical, effective, and high-quality applications based on one or more IBM Cloud™ services (for  example, web, mobile, data, analytics, AI, IoT, or weather) to mitigate the  impact of COVID-19. 

Topics: Creation of IBM Cloud™-based, open-source applications to mitigate the impact of COVID-19, for example, by improving crisis communications or fostering remote learning and community cooperation.

Due Dates: 7/31/2020
Budget: One $200,000 grand prize; two $25,000 first and second runner-up prizes; two $10,000 third and fourth runner-up prizes

West Coast Consortium for Technology & Innovation in Pediatrics (CTIP)
West Coast Consortium for Technology & Innovation in Pediatrics (CTIP)

Description: The West Coast Consortium for Technology & Innovation in Pediatrics (CTIP) is announcing a limited grant opportunity to support pediatric medical device innovators who are able to use their technology to aid in the current COVID-19 pandemic.

Topics: Pediatric medical device development or adaptation to manage the impact of COVID-19 on children

Due Dates: Accepting applications on a rolling basis
Budget: $15,000

Robert Wood Johnson Foundation DEADLINE APPROACHING
Emergency Response for the Health Care System – Innovation Challenge

Description: This challenge encourages applicants to design a novel digital tool to support the health care system during a large-scale health crisis.

Topics: Digital health tools addressing various topics, including:

  • Capacity management
  • Clinical integration (to coordinate patient care)
  • Communication
  • Data analytics, tracking, and visualization
  • Data exchange
  • Mental health tools for providers

Due Dates: 6/12/2020 (Phase I) and 8/18/2020 (Phase II)
Budget: Five semifinalists will receive $1,000 prizes; three finalists will receive prizes of $5,000 (3rd place), $15,000 (2nd place), and $25,000 (1st place)

Emergency Response for the General Public – Innovation Challenge

Description: This challenge encourages applicants to design a digital health technology tool to support the needs of individuals affected by a large-scale health crisis.

Topics: Digital health tools addressing the needs of individuals, including:

  • Health care access
  • Medication access
  • Access to other essential resources (e.g., diagnostic testing)
  • Information dissemination (e.g., clinical guidelines and recommendations)
  • Communication
  • Behavioral and emotional health

Due Dates: 6/12/2020 (Phase I) and 8/18/2020 (Phase II)
Budget: Five semifinalists will receive $1,000 prizes; three finalists will receive prizes of $5,000 (3rd place), $15,000 (2nd place), and $25,000 (1st place)

International Opportunities DEADLINE APPROACHING

Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro – FAPERJ

Emergency Action Projects to Combat the Effects of Covid-19 – FAPERJ / SES Partnership – 2020

Description: FAPERJ is providing funding to continue the work of networks in Brazil studying emerging and reemerging viruses and to finance the study of Covid-19 and the SARS-CoV-2 virus by various organizations, including startups and small, micro, and medium-sized companies based in the State of Rio de Janeiro.


  • Genomics
  • Pathophysiology of the disease
  • Clinical aspects
  • Diagnosis of the disease
  • Epidemiology
  • Virus-host interaction
  • Development of diagnostic kits
  • Disease control and coping strategies
  • Innovative solutions to expand supplies of items such as masks, alcohol gel, and respirators

Due Dates: Applications are accepted on a rolling basis
Budget: Not specified


Genome Canada

COVID-19 Regional Genomics Initiative

Description: Genome Canada is issuing a funding opportunity to support regional genomics projects designed to address specific, short-term needs of industry, not-for-profit, and public sector recipients through research conducted by academics in collaboration with these recipients. Projects are expected to be outcome-driven, small-scale or larger (depending on other funding sources) and focused on delivering a genomics-based solution to help address the current crisis in the near term.

Topics: Examples of relevant topics include:

  • Identifying and detecting COVID-19 infections
  • Understanding mechanisms of infection
  • Mapping the spread in real time
  • Tracking new mutations
  • Developing drug treatments or vaccines for the disease

Due Dates: Accepting applications on a rolling basis until 7/1/2020
Budget: Not specified ($250,000 [CAD] allocated per Genome Center)

National Research Council Canada

National Research Council Industrial Research Assistance Program (NRC IRAP)

Description: NRC Canada is offering project funding to small and medium-sized businesses that are working to provide COVID-19 solutions in the form of goods or services to health care workers and public health officials currently fighting the pandemic.

Topics: Development of COVID-19 solutions for health care workers and public health officials

Due Dates: None; applicants directly contact an Industrial Technology Advisor at NRC
Budget: Not specified


Novo Nordisk Foundation

View Application Information (Danish)

Eligibility: Public or private institutions in Denmark


  • Scientific projects that test new treatments, techniques and technologies or preventive initiatives that can rapidly be used to manage the challenges the health system faces in the current situation;
  • Information and outreach initiatives that can improve the communication to the public and their understanding and knowledge about how the health aspects of the crisis are being managed; and
  • Social initiatives designed to meet the special health needs of vulnerable groups affected by the crisis.

Budget: Up to DDK 5 million
Due Date: Applications accepted through 6/18/2020
Note: Application turnaround time is ~48 hours

Eureka (Multiple Participating Nations)

Solutions for the next human high-impact pandemic

Description: Eureka is seeking proposals for collaborative projects involving at least two independent organizations from different participating countries.

Topics: Topics include (but are not limited to):

  • Technologies enabling local resilience or self sufficiency
  • Medical intervention robotics
  • Infection prevention and protection
  • Prevention of antibiotic resistance
  • Sanitation technology
  • Diagnostics and testing
  • Therapeutics, vaccines and medicines
  • Medical intervention robotics
  • Disease-tracking technology
  • Smart technologies for critical production and supply chains under lockdown
  • Education technologies and digital workplace
  • Govtech/Open data and Big Data

Due Dates: 7/15/2020
Budget: Not specified


AMable/European Commission

AMable Open Call for Solution Ideas (COVID-19)

Description: AMable is seeking challenges related to COVID-19 and solutions that use additive manufacturing.

Topics: Challenges will involve a lack of equipment, helpful tools, replacement parts or parts that enable additional functionality.

Due Dates: 10/1/2020
Budget: €10,000 per challenge

The European Commission

Horizon 2020—Second call for an Expression of Interest for innovative and rapid health-related approaches to respond to COVID-19 and to deliver quick results for society for a higher level of preparedness of health systems

Description: The Horizon 2020 Framework Programme has released 5 topics for COVID-19-related research funding. For most of the topics, the Programme is seeking collaborative proposals from entities located in at least three different EU Member States or Horizon 2020-associated countries.


  • Repurposing of manufacturing for vital medical supplies and equipment (SC1-PHE-CORONAVIRUS-2020-2A)
  • Medical technologies, Digital tools and Artificial Intelligence (AI) analytics to improve surveillance and care at high Technology Readiness Levels (SC1-PHE-CORONAVIRUS-2020-2B)
  • Behavioural, social and economic impacts of the outbreak response (SC1-PHE-CORONAVIRUS-2020-2C)
  • Pan-European COVID-19 cohorts (SC1-PHE-CORONAVIRUS-2020-2D)
  • Networking of existing EU and international cohorts of relevance to COVID-19(SC1-PHE-CORONAVIRUS-2020-2E)

Due Dates: 6/11/2020
Budget: Not specified



Special call for proposals: Development of innovative technologies & methods to fight SARS-CoV-2

Description: The DIM ELICIT organization would like to support collaborative projects developing innovative technologies and methods for the analysis, diagnosis and/or treatment of SARS-CoV-2. The program is open to research teams in the Ile de France region.

Topics: The technologies targeted in this call must belong to at least one core technology and one end-user application from the following lists:

Core technologies:

  • Microfludics
  • Biophotonic and waves
  • Image analysis and Big Data

End-user applications:

  • Single cell/Single molecule
  • Organ-on-a-chip
  • Technologies for in vivo biology
  • High-tech, low-cost technologies

Due Dates: Applications are accepted on a rolling basis
Budget: €15k for running and/or staff costs; €30k for equipment

Agence Nationale de la Recherche (ANR)

Research Action COVID-19 (RA-COVID-19)

Description: The ANR is launching a new call for Research-Action projects on COVID-19, focusing on WHO recommendations.


  • Epidemiological studies
  • Physiopathogenesis of the disease
  • Infection prevention and control
  • Ethics and social dynamics
  • Global issues of the Covid-19 epidemic

Due Dates: 10/28/2020
Budget: €150,000


Merck KGaA

Research Grant for Pandemic Preparedness

Description: Merck will consider proposals that leverage technological solutions to be more prepared for pandemic outbreaks or solutions that could help to fight emerging viral infections.


Pre-outbreak R&D Preparedness for pandemic disease:

  • Assessing the priority of pathogens and diseases with epidemic threat
  • Platform technologies to accelerate the development of vaccines, drugs, diagnostics, vector control tools and delivery systems needed to control emerging health threats
  • Innovative technologies for better personal protection equipment for infection control

Response during outbreak:

  • Novel health technologies (e.g. AI, bioelectronics, diagnostics) for early screening of potential infected patients and treatment facilitation.
  • Fast-track identifying, testing and production of effective drugs and vaccines during outbreak

Due Dates: Applications will be reviewed on a rolling basis
Budget: €500,000 per year

Deutsche Forschungsgemeinschaft (German Research Foundation)

View Solicitation (English)

Topics: Prevention, early detection, containment and investigation of the causes, impacts and management of epidemics and pandemics

Due Date: Letter of Intent – 7/1/2020; Full Proposal – 9/1/2020
Budget: Not Specified


Malta Council for Science and Technology and Malta Enterprise Corporation

COVID-19 R&D Fund

Description: The Malta Council for Science and Technology and Malta Enterprise Corporation have announced a €5.3 Million COVID-19 R&D Fund targeting public, academic, and private entities to enable R&D on COVID-19. The fund is especially interested in projects with outcomes not only addressing innovative and/or improved approaches related to the current pandemic but also potential future waves and other antiviral relevant research.


  • Relevant medicinal products (including vaccines) and treatments, their intermediates, active pharmaceutical ingredients and raw materials
  • Medical devices, hospital and medical equipment (including ventilators and protective clothing and equipment as well as diagnostic tools) and necessary raw materials
  • Disinfectants and their intermediary products and raw chemical materials necessary for their production
  • Data collection and processing tools related to innovative and/or improved approaches with regards to current and/or future infectious disease prevention; o trajectory of the epidemic/pandemic disease
  • Better dissemination of recommendations by national (Public Health) and/or international health authorities (WHO)
  • Any other research related to infectious diseases that can lead to epidemics in humans

Due Dates: Applications are accepted on a rolling basis until 11/30/2020.
Budget: Not specified


Ministry of Science and Innovation

Solicitud Urgente de Expresiones de Interés para la Financiación Extraordinaria de Proyectos de Investigación sobre el SARS-CoV-2 y la Enfermedad COVID-19 (Spanish)


  • Scalable rapid diagnostic techniques for SARS-CoV-2, especially related to early stage detection and healthcare stratification
  • Clinical, biological, and molecular characteristics of COVID-19
  • Therapeutic development, including pharmaceutical and non-pharmaceutical measures
  • Antiviral resistance studies
  • Vaccine development
  • Socioeconomic impact of COVID-19
  • Integrated epidemiological controls, including AI and Big Data

Due Date: Ongoing
Budget: Not Specified; Total Program Budget €24,000,000



Innovations to mitigate the crisis: Finding new ways in the time of a crisis

Description: Vinnova is calling for innovative ideas to address the wider impact of the coronavirus crisis and support Swedish society. New solutions should be ready to be put into practice within six to twelve months.

Topics: Any new coronavirus-related need addressed through the conversion of production or activities, where a first solution is ready within 6-12 months

Due Dates: 6/10/2020 and 8/21/2020
Budget: Up to SEK 1,000,000

United Kingdom

UK Research and Innovation (UKRI)

Proposals will be accepted from anyone who is normally eligible to apply for UKRI funding. You will need to show that you can start work within 4 weeks of the funding being confirmed.

View Solicitation

Topics: Short-term projects (12-18 months) addressing and mitigating the health, social, economic, cultural and environmental impacts of the COVID-19 outbreak.

Due Date: Ongoing
Budget: 80% of the full economic cost

COVID-19 Rapid Response Rolling Call

Description: UKRI has announced a call for proposals for UK-led academic, small and medium-sized enterprise, and wider industry research that will address a wide range of COVID-19 knowledge gaps/needs, and which will lead to a benefit in UK, potentially international, public health within 12 months.


  • Virology, immunity and pathophysiology
  • Diagnostics
  • Epidemiology
  • Personal protective equipment
  • Infection prevention and control measures
  • Public Health, Media and Communication
  • Clinical Management
  • Primary, Adjunctive and Supportive Therapies
  • Vaccines
  • Health and care delivery
  • Assays and animal models
  • Research infrastructure

Due Dates: Applications are accepted and reviewed on a rolling basis until 4/1/2021
Budget: Not limited, but must reflect the needs of the research project

Get funding for ideas that address COVID-19

Description: Proposals are invited for short-term projects addressing and mitigating the health, social, economic, cultural, and environmental impacts of the COVID-19 outbreak. 

Topics: An extensive list of research questions can be found at These questions focus on various areas, including:

  • COVID-19 treatments
  • Contact tracing
  • Epidemiology
  • Data availability and use
  • Modeling and prediction
  • Accelerated use of AI and automation
  • National security and geopolitics
  • Engineering
  • Inequalities
  • Behavioral insights

Due Dates: None. Applications are accepted on a rolling basis.
Budget: Not specified